 Blueprint Medicines Corporation NASDAQ: BPMC, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion, recommending conditional marketing authorization for avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors GIST harboring the PDGFRA D842V mutation. 